DCTHライブシグナル | Getagraph.comで利益を最大化

買う 109570 min ago

@ $4.59

発行日: 13 2月 2024 @ 23:32

リターン: 18.74%

前回のシグナル: 2月 7 - 00:18

前回のシグナル: 売る

リターン: -0.33 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:41):

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe...

Stats
本日の出来高	92 082.00
平均出来高	213 420
時価総額	133.87M
EPS	$0 ( 2024-03-26 )
次の収益日	( $-0.430 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.850
ATR14	$0.0170 (0.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-19	Aharon Gil	Buy	26 882	Common Shares
2024-03-19	Salamon Steven A J	Buy	26 882	Common Shares
2024-03-19	Rosalind Advisors, Inc.	Buy	619 946	Pre-funded Warrants
2024-03-18	Rook Martha S.	Buy	125 000	Employee Stock Option (Right to Buy)
2024-03-18	Rook Martha S.	Buy	0

INSIDER POWER
93.89
Last 96 transactions
Buy: 8 343 756 \| Sell: 533 108

ボリューム相関

長: 0.15 (neutral)

短: 0.05 (neutral)

Signal:(73.313) Neutral

Delcath Systems Inc 相関

10 最も正の相関
META	0.947
JBSS	0.939
MANH	0.938
DSGX	0.937
CIFR	0.933
INOD	0.932
NVCT	0.932
ASO	0.932
IOAC	0.932
LIBY	0.931

10 最も負の相関
NCBS	-0.944
TSHA	-0.922
BWB	-0.915
GSMG	-0.915
IPA	-0.911
ALRS	-0.903
HLIO	-0.902
COFS	-0.901
CYRN	-0.9
GXGX	-0.899

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Delcath Systems Inc 相関 - 通貨/商品

-0.09
( neutral )

0.41
( neutral )

0.00
( neutral )

-0.17
( neutral )

-0.28
( neutral )

-0.42
( neutral )

Delcath Systems Inc 財務諸表

Annual	2023
収益:	$2.07M
総利益:	$1.30M (63.05 %)
EPS:	$-2.94

FY	2023
収益:	$2.07M
総利益:	$1.30M (63.05 %)
EPS:	$-2.94

FY	2022
収益:	$2.72M
総利益:	$2.03M (74.77 %)
EPS:	$-4.42

FY	2021
収益:	$3.56M
総利益:	$2.88M (81.13 %)
EPS:	$-8.85

Financial Reports:

No articles found.

Delcath Systems Inc

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.